In short, the overuse and inept use of antibiotics (for example, to "treat" viral infections or prematurely discontinue therapy) have made more and more bacteria resistant to them, making it difficult to treat many diseases. And while we are still developing new antibiotics, the process is not fast enough to keep up with the bacteria - luckily, there is a light in the tunnel, and we are talking about antibiotics to be used together and antibiotics to reduce the development of bacterial resistance. This is a perfect example of how evolution works, because when a drug wipes out a bacterial population, a few out of several million will survive, often due to random genetic mutations, and will pass on new immunity to the next generation.
Over time, drugs can therefore become ineffective against whole species of bacteria, which could lead us back to the dark age of medicine, where the most common infection can be fatal. Therefore, information from scientists at Pennsylvania State University and the University of Michigan is very promising: `` We have created a therapy that can help fight resistance development, antibiotics that allow antibiotics to do their job but without evolution and further transmission of resistance, '' explains one of the authors, Andrew Read.
The team focused on Enterococcus faecium, a bacteria commonly found in the gut - it is harmless there, but when it enters other parts of the body it causes serious infections such as sepsis. Especially its extremely dangerous strain, resistant to vancomycin, ie MRE (Vancomycin-Resistant Enterococcus), which we have been fighting somehow by administering daptomycin, but ... to this one is already becoming resistant. All because with the therapy some of the bacteria are literally hidden in the intestines, causing the evolution of the entire local population.
Scientists have found a way to protect the intestinal bacterial population from the administered antibiotic, using an already known drug that turns out to bind daptomycin and, according to the scientists, limits the area of action of the antibiotic. The tests in mice confirmed this hypothesis, because the simultaneous administration of drugs led to a reduction in the amount of VRE in the stool by 80%, so tests in humans should be expected soon, especially movies front the cholestyramine in question has long been approved for treatment.